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Case Report
Hand-Assisted Laparoscopic Partial Nephrectomy
for Large Renal Carcinoma with Succinate
Dehydrogenase Deficiency
Ann Buhl Bersang, MD,1 Sarah Bube, MD,1 Mikkel Fode, MD, PhD,2 and Nessn H. Azawi, MD, PhD1
Abstract
Background: Germline mutations in succinate dehydrogenase (SDH) are associated with multifocal cancers:
pituitary gland tumors, pheochromocytomas, paragangliomas, gastrointestinal stromal tumors, and renal-cell
carcinomas (RCCs). SDH-deficient renal-cell carcinoma (SDH-RCC) was first identified in 2004 as an inherited
kidney cancer with mutations in the SDH gene. SDH consists of A, B, C, and D units. Mutation in the SDHB
gene is the most common mutation in SDH-deficient RCCs.
Case Presentation: We report a case of a 51-year-old healthy man diagnosed with SDHB germline mutation
and RCCs. Positron emission tomography/computed tomography (PET/CT) showed a 12 cm tumor in the upper
pole of the left kidney. A hand-assisted laparoscopic partial nephrectomy was performed and the histopathology
of the tumor showed SDH-deficient RCC with clear surgical margins. Six months after the initial presentation,
the patient had a slightly impaired renal function and was disease-free on PET/CT.
Conclusion: Patients with SDH-deficient RCC are at risk of multifocal kidney tumors and should be offered
lifelong follow-up. To preserve the renal function, nephron-sparing surgery is the choice of treatment when
feasible, regardless of tumor size.
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Introduction and Background
Succinate dehydrogenase (SDH) is a heterotetramericprotein consisting of A, B, C, and D subunits located on
the inner mitochondrial membrane. SDH has an important
role in cellular energy metabolism in the Krebs cycle and as
part of the respiratory chain.1
Vanharanta et al. first identified SDH-deficient renal-cell
carcinoma (SDH-RCC) in 2004 as an inherited kidney
cancer with mutations in the SDH gene.1 The mutation was
also shown to be associated with pituitary gland tumors,
pheochromocytomas (PCCs), paragangliomas (PGLs), and
gastrointestinal stromal tumors (GISTs).2,3 Ricketts et al.
described in 2012 that SDH-RCC can develop regardless of
mutation history.2 In 2013, SDH-RCC was integrated into
the International Society of Urological Pathology Vancou-
ver Classification.4
Presentation of Case
We report a case of a healthy 51-year-old man with known
SDH deficiency in the family. The patient’s nephew was
diagnosed with PGL and a gene analysis identified the SDHB
gene mutation. Hence, DNA analysis was performed on the
rest of the family members.
The patient’s DNA analysis showed SDHB deficiency and
in February 2017, as part of the primary assessment, a posi-
tron emission tomography/computed tomography (PET/CT)
scan was performed because of the high risk of multifocal
disease. The scan demonstrated an 11.8 · 10.4 cm tumor in
the upper pole of the left kidney (Fig. 1). However, the scan
showed no sign of metastatic disease. The renal tumor an-
atomical classification according to the PADUA score was
estimated to 12. The patient had a history of back pain for
many years prior for diagnosis and explained that he had
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recently started to feel pain in the left hypochondria. The
patient had not experienced hematuria.
A hand-assisted laparoscopic partial nephrectomy was
performed on the 20th of March 2017 with off-clamping
technique to preserve the renal function. The estimated blood
loss was 600mL with a surgical time of 143 minutes. The
surgery was performed by a senior consultant who had pre-
viously performed >130 partial nephrectomies. There were
no complications reported within the first 30 postoperative
days. Regarding the renal function, the estimate glomerular
filtration rate was 90mL/min 1.73m2 preoperatively, at 1
month postoperative it was 79mL/min 1.73m2, and at 7
months postoperative it was 62mL/min 1.73m2.
The histopathology of the tumor revealed SDH-RCC with
clear margins, no sarcomatoid dedifferentiation, no necrosis,
and no pleomorphic tumor cells (Fuhrman grade 1; Fig. 2). A
6-month follow-up with fluorodeoxyglucose (FDG) PET/CT
was planned.
Four months after the surgery, the patient contacted the
hospital with pain in the left hypochondria throughout 5 days
and described it like the initial pain. Despite the pain, the 6-
month planned FDG PET/CT was performed in August 2017.
The scan revealed activity in the lungs and in mediastinal
lymph nodes. A biopsy of the lungs showed nomalignity. The
patient also complained of alternating stools, and subse-
quently a colonoscopy was performed—again with no ab-
normal findings. Further follow-up control was changed
because of the activity in the mediastinal lymph nodes. Scans
were planned for every 3 months during the first year and
afterward every 6 months during the subsequent 3 years and
annually after that.
Discussion and Literature Review
The frequency of SDH-RCC in all RCCs is estimated to be
between 0.05% and 0.2%.4 In SDH-RCC, the male:female
ratio is 1.8:1 and the average mean age of debut is reported
to be 33, 38, and 37 years, respectively.2–4 Gill et al. reported
an average tumor size of SDH-RCC of 51mm (range 7–
90mm).4 The most common SDH mutation in SDH-RCC is
SDHB deficiency followed by SDHC and SDHD deficien-
cy.1,2 Owing to these findings, patients with early onset (age
<45) RCC, with bilateral or multifocal renal tumors, should
be considered for SDH germline mutation testing.2 Further-
more, patients with SDH deficiency tumors of the pituitary
gland, PGL, PCC, or GIST, should be considered for test-
ing.2,3 Everyone with an SDH germline mutation in the
family should be offered a DNA analysis. Our patient un-
derwent genetic evaluation at an age of 51 years because of a
family history of mutation in the SDHB gene and was sub-
sequently found to have a 12 cm tumor in the left kidney.
Previous studies have recommended nephron-sparing sur-
gery because of the high risk of bilateral tumors and the
lifelong risk of recurring renal tumors.2,4 SDH deficiency
patients are young at time of diagnosis and are at risk of
multifocal tumors and oncologic treatments, thus depending
on as much renal function as possible supporting nephron-
sparing surgery.2–4 Despite the large tumor size localized to
the upper pole of the left kidney, we, therefore, chose to
perform a partial nephrectomy with off-clamping technique,
which was carried out effectively.
In 2014, Gill et al. observed metastatic disease in 9 out of
27 patients of which 2 patients experienced a late recurrence
in, respectively, 5.5 and 30 years after initial presentation.
The risk of metastatic disease increased with high grade
nuclei and coagulative necrosis, whereas metastatic disease
was rare in conjunction with low-grade tumors.4 Therefore,
extended—if not lifelong—surveillance is recommended.2–4
In our case, the 6 months’ control PET/CT scan showed no
sign of metastatic disease.
Conclusion
Patients with early onset RCC, those with a family history
of genetic mutation, should be considered for gene testing
and life-long follow-up in case of an SDH germline mutation.
Further evidence is needed to establish the appropriate
FIG. 1. Twelve centimeter tumor on the upper pole of left
kidney.
FIG. 2. Succinate dehydrogenase-deficient renal-cell
carcinoma. 20 · enlarged. Hematoxylin-eosin.
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management for SDH-RCC. At our department, we are ad-
vocating nephron-sparing surgery whenever feasible, re-
gardless of tumor size, because of the possibility of bilateral
renal tumors, multifocality, and low metastatic risk, as il-
lustrated in our case. Our case also shows that treatment by
partial nephrectomy in such patients is feasible in expert
hands even in large tumors. Furthermore, we were able to
perform the surgery with an off-clamp technique, thereby
protecting the remaining tissue from ischemia, and reducing
the loss of renal function.
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GISTs ¼ gastrointestinal stromal tumors
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PET/CT ¼ positron emission tomography/computed
tomography
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SDH ¼ succinate dehydrogenase
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